GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Credit Losses Provision

Marker Therapeutics (FRA:GX1) Credit Losses Provision


View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Credit Losses Provision?

Credit Losses Provision only applies to banks.


Marker Therapeutics (FRA:GX1) Business Description

Traded in Other Exchanges
Address
4551 Kennedy Commerce Drive, Houston, TX, USA, 77032
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.